Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Urology
Title   A phase II, randomized, controlled, efficacy assessor blinded, multi-center, international prospective study to assess the safety and effectiveness of Medi-Tate i-Temporary Implantable Nitinol Device (iTIND) in subjects with symptomatic Benign Prostatic
Summary   NYU Winthrop Hospital Department of Urology is conducting this clinical research study for men ages 50 and older who have symptomatic BPH.
Description   This study will evaluate the safety and efficacy of the Medi-Tate iTIND device for men with symptomatic BPH compared to a control. Participants will be randomly assigned to receive treatment with either the iTIND implantable device or a sham control procedure. The device will be inserted into the prostate through a cystoscope (a camera inserted into the bladder), and removed after 5-7 days.
IRB Number   16004
Inclusion/Notes   To be eligible for this clinical research study you must:
- Have benign prostatic hyperplasia (BPH) with symptoms (including but not limited to urinary hesitancy, weak stream, sensation of incomplete emptying)
- Have not had previous prostate surgery
Principal Name   Aaron Katz, MD
Contact Name   Kaitlin Kosinski, MS
Email   urologyresearch@nyuwinthrop.org
Phone   516-535-1900